Small Biotechs Show Their Cash Runways as Pipeline Readouts Loom
Praxis holds about $1.3 billion into 2028 with two FDA decisions ahead. Editas runs into late 2028, Turn into late 2027, and Abeona is already selling a gene therapy.
- Praxis Precision Medicines reported cash and investments of about $1.3 billion at September 30, 2026, enough to fund operations into 2028, with a net loss of $94.2 million in the quarter; the FDA target action dates are December 27, 2026, for relutrigine and January 29, 2027, for ulixacaltamide. Self-reported m:…1245
- Editas Medicine reported cash, cash equivalents and marketable securities of $190.2 million at September 30, 2026, expected to fund operations into the second half of 2028, with a net loss of $23.4 million; it won approval to start the Phase 1/2 Strive study of EDIT-401 in Australia. Self-reported m:…1591
- Turn Therapeutics expects its cash to fund operations into the third quarter of 2027; in the GX-03 Stage 1 trial, 59.3 percent of patients achieved clear or almost clear skin after four weeks, against 30.4 percent on vehicle, and 40.7 percent achieved EASI-100 at Week 8, against 17.4 percent on vehicle. Self-reported m:…1359
- Abeona Therapeutics reported third-quarter net ZEVASKYN revenue of $13.5 million, acquired the Phase 3-ready asset APT-1011 from Ellodi Pharmaceuticals for $20 million in common stock, agreed a $30 million private placement financing, and held $134.9 million in cash, cash equivalents and short-term investments at September 30, 2026, with a net loss of $4.8 million. Self-reported m:…4416
Praxis: the longest runway, the nearest decisions
Praxis Precision Medicines reported cash and investments of about $1.3 billion at September 30, 2026, the filing says, enough to maintain its runway into 2028. The company incurred a net loss of $94.2 million for the third quarter, with research and development expenses of $64.2 million and general and administrative expenses of $42.7 million. Two FDA reviews are now the deciding events: relutrigine, with a target action date of December 27, 2026, and ulixacaltamide, with a target action date of January 29, 2027. m:…1245
Topline results from the EMERALD study of relutrigine in broad developmental and epileptic encephalopathies are expected in the fourth quarter of 2026, the filing says, and Praxis expects to host an Investor Day on November 12, 2026. In July 2026 the company started a strategic collaboration with Remagine Labs to develop a transdermal patch of ulixacaltamide. Praxis had 27.9 million shares of common stock outstanding at September 30, 2026. m:…1245
Editas: gene editing with time to run
Editas Medicine reported cash, cash equivalents and marketable securities of $190.2 million at September 30, 2026, the filing says, and expects that cash to fund operating expenses and capital spending into the second half of 2028. The company reported a net loss of $23.4 million for the quarter. Collaboration and other research and development revenues rose to $10.4 million from $7.5 million a year earlier, while research and development expenses rose to $21.2 million from $19.8 million and general and administrative expenses to $13.5 million from $12.3 million. m:…1591
Editas received Human Research Ethics Committee approval in Australia and completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration to start the Phase 1/2 Strive study of EDIT-401. Preclinical data showed LDL cholesterol reduction of at least 90 percent maintained over 10 months in an ongoing study in non-human primates. A second IND/CTA was accepted for the CD70 HD Allo CAR T program under the collaboration with Bristol Myers Squibb, triggering a milestone payment to Editas; the filing does not disclose the amount. Dan Ory was appointed chief medical officer in September 2026. m:…1591
Turn: data first, cash second
Turn Therapeutics expects its cash to fund operations into the third quarter of 2027, the filing says, though it does not disclose the cash balance. The evidence it offered instead was clinical: in the Stage 1 trial of GX-03 for atopic dermatitis, 59.3 percent of patients achieved clear or almost clear skin after four weeks, compared with 30.4 percent receiving vehicle, and 40.7 percent achieved EASI-100 at Week 8, compared with 17.4 percent on vehicle. The ongoing Phase 2b trial is evaluating GX-03 in 120 to 136 atopic dermatitis patients and has recorded no patient dropouts to date. m:…1359
Robert R. Redfield was appointed chief scientific officer effective September 9, 2026. Turn expects to report topline results from the Phase 2b atopic dermatitis trial in the first quarter of 2027, and enrollment for the hidradenitis suppurativa trial is expected to begin in the first quarter of 2027. In animal studies, GX-03 reduced IL-36 by about 50 percent and IL-31 by nearly 68 percent. m:…1359
Abeona: already selling
Abeona Therapeutics is the one company in this group already selling a product. Net ZEVASKYN revenue for the quarter ended September 30, 2026, was $13.5 million, the filing says. The net loss was $4.8 million, or $0.08 per share. Cash, cash equivalents and short-term investments totaled $134.9 million at September 30, 2026. Revenue was not recognized for one treatment in the quarter because the batch did not meet the release criterion for the identity assay. Abeona expanded its ZEVASKYN QTC network to eight sites during the quarter. m:…4416
Abeona also announced the acquisition of the Phase 3-ready asset APT-1011, now ABO-801, from Ellodi Pharmaceuticals for $20 million in common stock, with Ellodi eligible for up to $60 million in milestone payments and tiered royalties, and a $30 million private placement financing. ZEVASKYN New Technology Add-on Payment status became effective October 1, 2026, to support hospital reimbursement. Abeona is also eligible for commercial milestone payments and royalties of up to 8 percent on FAYUVI sales from Ultragenyx. m:…4416
What is still unresolved
- The dollar amount of the milestone payment Editas received from Bristol Myers Squibb
- Final FDA approval decisions for relutrigine and ulixacaltamide
- The final regulatory approval timeline for ABO-801
- The specific timing for the use of Abeona's private placement financing proceeds
- Turn Therapeutics' cash balance, which the filing states only as a runway into the third quarter of 2027
Provenance by Synorb. Every claim links to its source. This story was written by an agent from the Manifests listed below. Read the methodology and limitations, or send a correction.
Free to reuse, including commercially. Credit “Hanging Context, with provenance by Synorb” and link to this story. Keep the cited Manifest ids. Reuse terms v1.